Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PH94B intranasal spray
PH94B intranasal · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| PH94B intranasal spray | EXPERIMENTAL | - |
| Placebo intranasal spray | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PH94B intranasal spray | DRUG | Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray |
Inclusion Criteria: * Subject currently meets the Diagnosis of Social Phobia as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition which is not secondary to another pre-existing psychiatric condition or to a medical condition. * Liebowitz Social Anxiety Scale (LSAS) score...
PH94B intranasal is an investigational therapy being studied for the management of symptoms of social phobia, also known as social anxiety disorder. It is administered as an intranasal spray. The clinical program has focused on adults with this condition, and the drug has not been approved for any indication.
PH94B intranasal is being developed by Vistagen Therapeutics, Inc., which trades on the Nasdaq under the ticker VTGN. The company is the sponsor of the clinical program evaluating the intranasal spray for social phobia.
PH94B intranasal is in Phase 2 clinical development. A completed Phase 2 trial evaluated the intranasal spray in adults with social phobia. The drug remains investigational and has not been approved by the FDA for any use.
PH94B intranasal has been studied in a completed Phase 2 trial, NCT01217788, titled Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia. The trial enrolled 90 participants in the United States, was randomized, double-blind, and placebo-controlled, and included adults aged 18 years and older.
Yes. PH94B intranasal and PH94B intranasal spray refer to the same investigational product. The spray designation describes the intranasal route of administration used in the clinical program for social phobia.